Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Morris, D."'
Autor:
Anna Skakodub, Lisa M. DeAngelis, Morris D. Groves, Adrienne Boire, Jeffrey Raizer, Michelle E. Melisko, Suriya Jeyapalan, Rachna Malani, Priya Kumthekar, Andrew D. Seidman, Elena Pentsova, Andrew B. Lassman, Xuling Lin, Antonio Omuro, Nan Lin, Marc K. Rosenblum, Martin Fleisher
Publikováno v:
Journal of Neuro-Oncology
Purpose The CellSearch® system has been used to identify circulating tumor cells (CTCs) in cerebrospinal fluid (CSF) to diagnose leptomeningeal metastasis (LM) in patients with epithelial cancers. Using this system, we prospectively explored sequent
Autor:
Monica Loghin, W. K. Alfred Yung, Stefania Maraka, Marta Penas-Prado, Charles A. Conrad, John de Groot, Erik P. Sulman, Kenneth Aldape, Barbara O’Brien, Ivo W. Tremont-Lukats, Mark R. Gilbert, Kenneth R. Hess, Morris D. Groves, Aaron Mammoser, Vinay K. Puduvalli, Isaac Melguizo-Gavilanes
Publikováno v:
Cancer. 125:424-433
BACKGROUND: Repurposed memantine, mefloquine, and metformin have putative anticancer activity. The objective of this phase 1 study was to determine the maximum tolerated doses (MTDs) of combinations of these agents with temozolomide (TMZ). METHODS: A
Autor:
Rohan Ramakrishna, Shirley Ong, Mariza Daras, Jason M. Melear, Brett Ewald, Adam M. Sonabend, Suresh G. Nair Md, Robert Aiken, Thomas Kaley, Laura Agensky, Timothy F. Cloughesy, Matteo Levisetti, Gelareh Zadeh, Vinay K. Puduvalli, Frederick F. Lang, Michael A. Vogelbaum, Howard Colman, Analiz Rodriguez, Simon Khagi, Priya Kumthekar, Morris D. Groves, Farshad Nassiri, Maxim Yankelevich, David M. Peereboom, Clark C. Chen
Publikováno v:
Neuro Oncol
BACKGROUND A Phase 2 multi-center study was conducted to evaluate the replication-competent oncolytic adenovirus, DNX-2401 (tasadenoturev), in combination with the anti-PD-1 antibody, pembrolizumab, in subjects with recurrent glioblastoma. METHODS Su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf4b9d18e9b530c256a7aae5c2ded911
https://europepmc.org/articles/PMC7678729/
https://europepmc.org/articles/PMC7678729/
Autor:
Silvia Hofer, Michael Glantz, Christopher Messner, Morris D. Groves, Suriya A. Jeyapalan, Dawit Aregawi, David Roberge, Roberta Rudà
Publikováno v:
Neuro Oncol
INTRODUCTION CSF cytology and neuraxis MRI scanning are complementary examinations for diagnosing NM. Positive cytology is the current gold standard despite relatively low sensitivity. Although MRI is an accepted alternative diagnostic tool for both
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ab307e320bbccd3af0675703fe61592
https://europepmc.org/articles/PMC6847435/
https://europepmc.org/articles/PMC6847435/
Autor:
Michael A. Vogelbaum, Farshad Nassiri, Clark C. Chen, Frank Tufaro, Shirley Ong, Adam M. Sonabend, Rohan Ramakrishna, Priya Kumthekar, Frederick Lang, Morris D. Groves, Barry Watkins, Gelareh Zadeh, Howard Colman, Carin Bidwell, Robert Aiken, Simon Khagi, Joanna Peterkin, Timothy F. Cloughesy, Laura Agensky, Mariza Daras
Publikováno v:
Neuro Oncol
BACKGROUND DNX-2401 (tasadenoturev) is a replication-competent, tumor-selective, oncolytic adenovirus. Phase I studies in adults with recurrent glioblastoma (rGBM) have demonstrated safety and encouraging clinical activity. A Phase II open-label, dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9729a46d32e41f44d380b45a4f07fb2f
https://europepmc.org/articles/PMC6847955/
https://europepmc.org/articles/PMC6847955/
Autor:
Morris D. Groves, J. Raizer, F.Y.F.L. De Vos, Patrick Roth, Andrew B. Lassman, K Steward, J M Gil-Gil, Vinay K. Puduvalli, Paul Clement, Juan M. Sepúlveda-Sánchez, T. Cloughesy, N. Butowski, C Belda-Iniesta, Y Ye, Patrick Y. Wen, S Moran
Publikováno v:
Neuro Oncol
BACKGROUND FGFR mutations and translocations occur in approximately 10% of glioblastomas (GBMs). FGFR3-TACC3 fusion has been reported as predictive of response to FGFR tyrosine kinase inhibitor therapy both pre-clinically and clinically. Infigratinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa371195fc0ef08b8ee6b5fc93b43318
https://europepmc.org/articles/PMC6795586/
https://europepmc.org/articles/PMC6795586/
Autor:
Manmeet Ahluwalia, Susan M. Chang, Michael A. Vogelbaum, Priscilla K. Brastianos, Michael Weller, Michael Glantz, Emilie Le Rhun, Adrienne Boire, Dieta Brandsma, Riccardo Soffietti, Morris D. Groves, Roberta Rudà, Jeffrey Raizer, Martin J. van den Bent, Larry Junck, Eudocia Q. Lee, Nan Lin, Patrick Y. Wen
Publikováno v:
Neuro-Oncology
Neuro-Oncology, 2019, 21 (5), pp.571-584. ⟨10.1093/neuonc/noz012⟩
Neuro-Oncology, 21(5), 571-583. Oxford University Press
Neuro-Oncology, Oxford University Press (OUP), 2019, 21 (5), pp.571-584. ⟨10.1093/neuonc/noz012⟩
Neuro-Oncology, 2019, 21 (5), pp.571-584. ⟨10.1093/neuonc/noz012⟩
Neuro-Oncology, 21(5), 571-583. Oxford University Press
Neuro-Oncology, Oxford University Press (OUP), 2019, 21 (5), pp.571-584. ⟨10.1093/neuonc/noz012⟩
International audience; Liquid biopsies collect and analyze tumor components in body fluids, and there is an increasing interest in the investigation of liquid biopsies as a surrogate for tumor tissue in the management of both primary and secondary b
Autor:
Kathryn Kolibaba, David Lorente Estelles, Craig Gedye, David Vicente, Carole Gourmelon, Mustafa Khasraw, David A. Reardon, Chee Lee, Michael Weller, Christoph Helwig, Macarena I. de la Fuente, Morris D. Groves, Laureen S. Ojalvo
BACKGROUND: TGF- signaling promotes tumor immunosuppression; TGF- inhibition in the tumor microenvironment may enhance the response to antiPD-L1 treatment. M7824 is an innovative, first-in-class, bifunctional fusion protein composed of a human antiPD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d60b6e9edd09e6617ca725207c79d7a
https://europepmc.org/articles/PMC6216129/
https://europepmc.org/articles/PMC6216129/
Autor:
Priya Kumthekar, Jeffrey Raizer, Sean Grimm, Andrew B. Lassman, Nan Lin, Elena Pentsova, Suriya A. Jeyapalan, Morris D. Groves, William J. Gradishar, Michelle E. Melisko
Pts with HER2+ breast cancer have frequent LM. No current FDA approvals exist. A multicenter phase I/II trial assessing safety and efficacy of IT T in LM pts was conducted. The primary endpoint in phase 2 was response rate (RR). Complete response (CR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5071757cce973df0fee4b161a5eebdca
https://europepmc.org/articles/PMC6216912/
https://europepmc.org/articles/PMC6216912/
Autor:
Morris D. Groves, Michelle E. Melisko, Xuling Lin, S Jeyapalan, Andrew B. Lassman, Nan Lin, J. Raizer, Adrienne Boire, Martin Fleisher, Lisa M. DeAngelis, Rachna Malani, Antonio Omuro, Elena Pentsova
BACKGROUND: The validated CellSearch system (Janssen Diagnostics, LLC), utilizing an immunomagnetic CTC selection method based on EPCAM antibody conjugated ferroparticles, is an FDA-approved methodology for enumerating CTC from blood in pts with brea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07ba2db57ccff19c8865e92c1d6f79b8
https://europepmc.org/articles/PMC6144227/
https://europepmc.org/articles/PMC6144227/